<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892748</url>
  </required_header>
  <id_info>
    <org_study_id>VITD59/11</org_study_id>
    <nct_id>NCT01892748</nct_id>
  </id_info>
  <brief_title>Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.</brief_title>
  <official_title>Effects of Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Onset Systemic Lupus Erythematosus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ROSA MARIA RODRIGUES PEREIRA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The potential role of vitamin D on disease susceptibility, activity and severity has been
      considered for several autoimmune rheumatologic diseases include systemic lupus erythematosus
      (SLE) . Although, there are few studies of vitamin D supplementation in SLE patients,
      especially in Juvenile Onset Systemic Lupus Erythematosus (JoSLE).

      The objective of this study is to evaluate the effect of vitamin D supplementation
      (cholecalciferol 50.000 international units (IU)/week for 24 weeks) on disease activity
      (clinical and laboratory parameters), fatigue and bone mass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study 24-week, two arm, double blinded randomized clinical trial to evaluate the
      effects of high-dose vitamin D3 supplementation compared with placebo, on activity disease,
      fatigue and bone mass.

      Sixty JoSLE patients will be randomized to receive placebo or vitamin D3 (50.000 IU/week) for
      24weeks. The patients return to visits in week 12 and week 24 for evaluation. Study will
      record clinical history, drugs in use, disease activity, and bone mass parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Disease Activity Score (SLEDAI)</measure>
    <time_frame>baseline to week 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Fatigue Score</measure>
    <time_frame>baseline to week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Bone Mineral Parameters</measure>
    <time_frame>baseline to week 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol 50.000IU/week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive vitamin D3 (50.000 IU/week) for 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive placebo in similar capsules of cholecalciferol for 24weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.</description>
    <arm_group_label>Cholecalciferol 50.000IU/week</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent signed

          -  4 of the 11 modified American College of Rheumatology (ACR) Revised Criteria for the
             Classification of Systemic Lupus Erythematosus .

          -  SLEDAI &lt; 8 at Screening and at Baseline

          -  Stable immunosuppressive dose prior to randomization.

          -  Body Mass Index &lt; 30

          -  Able to swallow pills at randomization

        Exclusion Criteria:

          -  Refuse of the patient or the legal responsible

          -  Use of vitamin D2 or D3 supplementation

          -  Significant renal insufficiency

          -  Primary hyperparathyroidism (known)

          -  History of nephrolithiasis (known)

          -  Diabetes mellitus requiring insulin therapy

          -  History of vertebral compression fractures (known)

          -  Pregnancy

          -  Use of bisphosphonates
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa MR Pereira, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo - School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glauce L Lima, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo - School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo - School of Medicine</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>ROSA MARIA RODRIGUES PEREIRA</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Juvenile</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Disease activity</keyword>
  <keyword>Bone Mass</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

